Peptides: the chaotic frontier

Thu, 23 Apr 2026 00:00:00 +0000

Abstract. BPC-157, TB-500, CJC-1295, Epithalon, MOTS-c: molecules that biohackers inject at home citing mouse preclinical data and before/after photos, without the trials we would take for granted for any other drug. Here I examine one by one what the literature actually says — the leap from mouse to human, the quality of substances on the grey market, the longevity clinics that exploit regulatory arbitrage to sell in Dubai what FDA and EMA have blocked. Follow-up to Living Forever.

On the biohacker catalogue, peptides occupy a peculiar position: more sophisticated than pharmacy supplements, more accessible than prescription drugs, wrapped in a scientific vocabulary that makes them seem like serious medicine without actually being so — not yet, perhaps never. It is a grey zone populated by real molecules, real literature, and claims that run much faster than the literature.

There are three mirror-image mistakes when discussing peptides. The first is to dismiss them as quackery: many have solid biological foundations, some have interesting preclinical literature, one or two are approaching serious clinical trials. The second is to treat them as finished drugs: none of the peptides on the grey market have the clinical documentation we would take for granted in any other therapeutic context. The third, more insidious, is to confuse mechanistic plausibility with clinical evidence. “It makes sense how it would work” is not the same thing as “we know it does good, in whom, at what doses, for how long, without which risks”. That distinction is everything.

This article tries to stand in that middle ground. To describe what they really are, where the claims come from, where the science stops and the marketing begins, and which peptides — today — have some basis to reason from, and which travel almost exclusively on anecdotes and before-and-after photos.

Peptides on noema

Peptides: the chaotic frontier